Literature DB >> 3816919

Hypotensive and antiplatelet actions of motapizone depend on dose and time after ingestion.

V Schulz, W Fischer, U Hanselle, W Huhmann, V Zietsch.   

Abstract

Single doses of motapizone 1 to 10 mg were given to 12 healthy subjects. Before and up to 8 h after each dose the blood pressure and heart rate were measured, as well as thrombocyte aggregation "ex vivo" with collagen, ADP and adrenaline. Motapizone produced a dose-dependent reduction in diastolic blood pressure and an increase in heart rate. These effects were demonstrated with individual variations after 1 to 3 mg and as a rule they were very marked after more than 6 mg. With the highest dose (mean 7.7 +/- 2.3 mg) the diastolic pressure fell by an average of 23% 1 h after medication as compared to with the baseline values. At the same time there was marked inhibition of thrombocyte aggregation, which also became apparent after about 3 mg and increased in proportion to the dose. The inhibition of aggregation peaked after 2 h and had disappeared within 8 h. The inhibition of ADP-induced aggregation was particularly marked.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3816919     DOI: 10.1007/bf00613514

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Acute effects of ethanol, caffeine, or both on platelet aggregation, thromboxane formation, and plasma-free fatty acids in normal subjects.

Authors:  C Galli; S Colli; G Gianfranceschi; P Maderna; A Petroni; E Tremoli; M Marinovich; C R Sirtori
Journal:  Drug Nutr Interact       Date:  1984

2.  Effect of the thromboxane synthetase inhibitor Dazoxiben (UK 37-248) on the metabolism of antipyrine in patients with enhanced platelet aggregation.

Authors:  C Staiger; E Walter; N S Wang; E Schuhmacher; J de Vries; E Weber
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-05

3.  Standardization of collagen: consideration of current practices in testing collagen-induced aggregation.

Authors:  M A Packham
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

4.  [Inhibition of platelet aggregation and thromboxane formation by the calcium antagonist nisoldipine following a single oral dose of 10 mg. A double-blind study in healthy probands].

Authors:  K Schrör; G Latta; H Darius; W Klaus; R Ziegler
Journal:  Klin Wochenschr       Date:  1985-01-02

5.  Time and temperature dependent changes of ADP - and collagen-induced and "spontaneous" aggregation.

Authors:  K Breddin; M Ziemen; O Bauer; W Herrmann; L Schaudinn; U Schlosser; A Winterhagen; H J Krzywanek
Journal:  Thromb Res       Date:  1980 Aug 15-Sep 1       Impact factor: 3.944

6.  Dipyridamole inhibits platelet aggregation in whole blood.

Authors:  P Gresele; C Zoja; H Deckmyn; J Arnout; J Vermylen; M Verstraete
Journal:  Thromb Haemost       Date:  1983-12-30       Impact factor: 5.249

7.  Inhibition of thrombocyte aggregation by oral motapizone and other drugs.

Authors:  V Schulz; W Fischer; U Hanselle; W Huhmann; V Zietsch
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

9.  Sources of variability in dose response platelet aggregometry.

Authors:  M V Vickers; S G Thompson
Journal:  Thromb Haemost       Date:  1985-04-22       Impact factor: 5.249

10.  Normal standards of in vitro induced platelet aggregation.

Authors:  W C Yip; T F Ho; J S Tay; P Han; H B Wong
Journal:  Ann Acad Med Singapore       Date:  1984-07       Impact factor: 2.473

View more
  1 in total

1.  Inhibition of thrombocyte aggregation by oral motapizone and other drugs.

Authors:  V Schulz; W Fischer; U Hanselle; W Huhmann; V Zietsch
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.